Amitriptyline is a tricyclic antidepressant with sedative effects. Amitriptyline affects certain chemical messengers (neurotransmitters) that communicate between brain cells and help to regulate the mood. The drug is indicated for treatment of major depressive disorder, neuropathic pain, the prophylactic treatment of chronic tension type headache (CTTH) and migraine in adults, also used in the treatment of nocturnal enuresis. It is available in tablet form.
Market Dynamics
Increasing prevalence of depression or bipolar disorder is expected to drive demand for tricyclic antidepressants such as Amitriptyline, thereby contributing to growth of the global amitriptyline market. According to the Global Burden of Disease Collaborative Network, in 2017, the prevalence of bipolar disorder ranged from 0.3% to 1.2% by country, and around 46 million people suffered from the bipolar disorder worldwide. Bipolar disorder is a brain disorder, also known as manic illness, which affects the mood, energy level, and other activities.
Key features of the study:
- This report provides in-depth analysis of the global amitriptyline market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global amitriptyline market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study are Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Sandoz Inc., Sun Pharmaceutical Industries Inc., Vintage Pharmaceuticals Inc., Zydus Pharmaceuticals USA Inc., Watson laboratories Inc., and Torrent Pharmaceuticals Ltd.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
- The global amitriptyline market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurofibromatosis treatment drugs market.
Detailed Segmentation:
- Global Amitriptyline Market, By Strength:
- 10 mg tablets
- 25 mg tablets
- 50 mg tablets
- 75 mg tablets
- 100 mg tablets
- 150 mg tablets
- Global Amitriptyline Market, By Indication:
- Depression
- Nocturnal Enuresis
- Migraine
- Chronic Neuropathic Pain
- Others
- Global Amitriptyline Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Amitriptyline Market, By Region:
- North America
- By Strength:
- 10 mg tablets
- 25 mg tablets
- 50 mg tablets
- 75 mg tablets
- 100 mg tablets
- 150 mg tablets
- By Indication:
- Depression
- Nocturnal Enuresis
- Migraine
- Chronic Neuropathic Pain
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Latin America
- By Strength:
- 10 mg tablets
- 25 mg tablets
- 50 mg tablets
- 75 mg tablets
- 100 mg tablets
- 150 mg tablets
- By Indication:
- Depression
- Nocturnal Enuresis
- Migraine
- Chronic Neuropathic Pain
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Strength:
- 10 mg tablets
- 25 mg tablets
- 50 mg tablets
- 75 mg tablets
- 100 mg tablets
- 150 mg tablets
- By Indication:
- Depression
- Nocturnal Enuresis
- Migraine
- Chronic Neuropathic Pain
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Strength:
- 10 mg tablets
- 25 mg tablets
- 50 mg tablets
- 75 mg tablets
- 100 mg tablets
- 150 mg tablets
- By Indication:
- Depression
- Nocturnal Enuresis
- Migraine
- Chronic Neuropathic Pain
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Strength:
- 10 mg tablets
- 25 mg tablets
- 50 mg tablets
- 75 mg tablets
- 100 mg tablets
- 150 mg tablets
- By Indication:
- Depression
- Nocturnal Enuresis
- Migraine
- Chronic Neuropathic Pain
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Strength:
- 10 mg tablets
- 25 mg tablets
- 50 mg tablets
- 75 mg tablets
- 100 mg tablets
- 150 mg tablets
- By Indication:
- Depression
- Nocturnal Enuresis
- Migraine
- Chronic Neuropathic Pain
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Accord Healthcare Inc.*
- Company Overview
- Strength Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Mylan Pharmaceuticals Inc.
- Sandoz Inc.
- Sun Pharmaceutical Industries Inc.
- Vintage Pharmaceuticals Inc.
- Zydus Pharmaceuticals USA Inc.
- Watson laboratories Inc.
- Torrent Pharmaceuticals Ltd.
“*” marked represents similar segmentation in other categories in the respective section.
